AstraZeneca Seen as Leader of Next Generation of Biologic Medicines -- Market Talk

Dow Jones03-31

1409 GMT - AstraZeneca is likely to lead in next-generation biologic medicines, a market that could generate at least $100 billion in U.S. revenue by 2045, Bernstein analysts say. Next-gen biologic technologies such as antibody-drug conjugates and bispecific antibodies are expected to expand quickly due to higher efficacy and less toxicity, according to Bernstein. Britain's AstraZeneca started to bet on this in 2019 via partnership with Daiichi Sankyo for antibody-drug conjugate Enhertu to treat cancer, and has invested heavily since then to build an in-house portfolio of next-gen biologics, the analysts say. "Hence, unlike its competitors, [AstraZeneca] is no longer reliant on economically dilutive partnerships," they add. The company's next-gen pipeline could generate global sales of $30 billion in 2045, Bernstein estimates. Shares rise 0.35%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

March 31, 2026 10:09 ET (14:09 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623803185?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 22:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623803185","market":"nz","top_or_hot":-1,"title":"AstraZeneca Seen as Leader of Next Generation of Biologic Medicines -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1409 GMT - AstraZeneca is likely to lead in next-generation biologic medicines, a market that could generate at least $100 billion in U.S. revenue by 2045, Bernstein analysts say. Next-gen biologic technologies such as antibody-drug conjugates and bispecific antibodies are expected to expand quickly due to higher efficacy and less toxicity, according to Bernstein. Britain's AstraZeneca started to bet on this in 2019 via partnership with <a href=\"https://laohu8.com/S/DSKY\">Daiichi Sankyo</a> for antibody-drug conjugate Enhertu to treat cancer, and has invested heavily since then to build an in-house portfolio of next-gen biologics, the analysts say. \"Hence, unlike its competitors, [AstraZeneca] is no longer reliant on economically dilutive partnerships,\" they add. The company's next-gen pipeline could generate global sales of $30 billion in 2045, Bernstein estimates. Shares rise 0.35%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 31, 2026 10:09 ET (14:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Seen as Leader of Next Generation of Biologic Medicines -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Seen as Leader of Next Generation of Biologic Medicines -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-31 22:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1409 GMT - AstraZeneca is likely to lead in next-generation biologic medicines, a market that could generate at least $100 billion in U.S. revenue by 2045, Bernstein analysts say. Next-gen biologic technologies such as antibody-drug conjugates and bispecific antibodies are expected to expand quickly due to higher efficacy and less toxicity, according to Bernstein. Britain's AstraZeneca started to bet on this in 2019 via partnership with <a href=\"https://laohu8.com/S/DSKY\">Daiichi Sankyo</a> for antibody-drug conjugate Enhertu to treat cancer, and has invested heavily since then to build an in-house portfolio of next-gen biologics, the analysts say. \"Hence, unlike its competitors, [AstraZeneca] is no longer reliant on economically dilutive partnerships,\" they add. The company's next-gen pipeline could generate global sales of $30 billion in 2045, Bernstein estimates. Shares rise 0.35%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 31, 2026 10:09 ET (14:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2456880835.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2623803185","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623803185","pubTimestamp":1774966140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1409 GMT - AstraZeneca is likely to lead in next-generation biologic medicines, a market that could generate at least $100 billion in U.S. revenue by 2045, Bernstein analysts say. Next-gen biologic technologies such as antibody-drug conjugates and bispecific antibodies are expected to expand quickly due to higher efficacy and less toxicity, according to Bernstein. Britain's AstraZeneca started to bet on this in 2019 via partnership with Daiichi Sankyo for antibody-drug conjugate Enhertu to treat cancer, and has invested heavily since then to build an in-house portfolio of next-gen biologics, the analysts say. \"Hence, unlike its competitors, [AstraZeneca] is no longer reliant on economically dilutive partnerships,\" they add. The company's next-gen pipeline could generate global sales of $30 billion in 2045, Bernstein estimates. Shares rise 0.35%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4568":"美国抗疫概念","BK4588":"碎股","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","AZN":"阿斯利康","BK4007":"制药","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","MDCO":"麦迪逊医药","BK4585":"ETF&股票定投概念","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H"},"translate_title":"阿斯利康被视为下一代生物药的领导者——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9,"MDCO":1.5},"content_text":"1409 GMT - AstraZeneca is likely to lead in next-generation biologic medicines, a market that could generate at least $100 billion in U.S. revenue by 2045, Bernstein analysts say. Next-gen biologic technologies such as antibody-drug conjugates and bispecific antibodies are expected to expand quickly due to higher efficacy and less toxicity, according to Bernstein. Britain's AstraZeneca started to bet on this in 2019 via partnership with Daiichi Sankyo for antibody-drug conjugate Enhertu to treat cancer, and has invested heavily since then to build an in-house portfolio of next-gen biologics, the analysts say. \"Hence, unlike its competitors, [AstraZeneca] is no longer reliant on economically dilutive partnerships,\" they add. The company's next-gen pipeline could generate global sales of $30 billion in 2045, Bernstein estimates. Shares rise 0.35%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2026 10:09 ET (14:09 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623803185","isCrawlerRequest":true}